<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088243</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2360B</org_study_id>
    <nct_id>NCT01088243</nct_id>
  </id_info>
  <brief_title>Targeting Oxidative Stress in Chronic Beryllium Disease</brief_title>
  <official_title>Targeting Oxidative Stress in Chronic Beryllium Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand if a drug called mesalamine helps to control
      inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD
      subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive
      effects of prednisone, and thus reduce the immune response to beryllium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this study is to understand the role of oxidative stress as a potential
      therapeutic target in the pathogenesis of chronic beryllium disease (CBD). CBD is an
      inflammatory hypersensitivity lung disease that occurs in an estimated 800,000
      beryllium-exposed workers in the United Sates. CBD is characterized by the presence of
      pulmonary non-caseating granulomas with accumulation of macrophages and beryllium specific
      CD4+ T cells (Newman et al. 1998). Upon beryllium stimulation in vitro, beryllium specific
      CD4+ T cells proliferate and produce Th1 cytokines (i.e. TNF-α, IFN-γ, and IL-2) at unusually
      high levels (Tinkle et al. 1997). The molecular mechanism(s) by which beryllium regulates the
      chronic production of these cytokines is unknown. Exciting preliminary studies indicate that
      beryllium alters the redox status of T cells which may adversely modulate the immune response
      in CBD. Based on these points, a novel hypothesis is proposed: 1) oxidative stress enhances
      the T cells response to antigen and this enhancement may explain both the excessive cytokine
      response and the pathogenesis of pulmonary granulomas in CBD and; 2) an inherent difference
      in T cell antioxidant status is a critical factor in the pathogenesis of CBD. This proposal
      is a pilot clinical trial examining an approved drug for the treatment of ulcerative colitis
      (5-amino salicylic acid, 5-ASA), which has anti-inflammatory and antioxidant properties, as a
      potential new approach for CBD treatment. In this clinical trial, 40 CBD subjects already
      treated with prednisone, will be treated with either placebo or 5-ASA to determine it effects
      on the beryllium stimulated immune response in the lung by undergoing bronchoscopy with
      bronchoalveolar lavage and in blood by undergoing venipuncture before and after 6 weeks of
      treatment with 5-ASA. As a secondary outcome, we will also assess subjects clinical response
      to this short course of 5-ASA using spirometry. Bronchoscopies are optional. Patients have
      the option to participate by undergoing venipuncture and lung function tests only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Primary endpoints are beryllium proliferation responses (BeLPT) in PBMCs (peripheral blood mononuclear cells) and BAL (bronchoalveolar lavage) cells. The BeLPT is a blood test that measures the immune response to beryllium exposure. If immune cells multiply in response to beryllium, this is considered an abnormal test results. If immune cells do not multiple, this is considered a normal test results. Results are reported as &quot;stimulation index&quot;, which is a ratio of the number of cells grown with beryllium compared to the number of cells grown without beryllium. A value of 2.5 or less is considered normal, and a value greater than 2.5 is abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Bronchoalveolar Lavage (BAL) Tumor Necrosis Factor Alpha (TNFa)</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Secondary outcomes include changes in bronchoalveolar lavage (BAL) tumor necrosis factor alpha (TNFa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Steady-state Glutathione (GSH) Levels From Baseline to Week 6</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Secondary outcomes include changes in steady-state GSH levels in beryllium specific CD4+ T cell in bronchoalveolar lavage fluid (BALF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDAC2 Levels</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Secondary outcomes include changes in HDAC2 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid Receptors</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Secondary outcomes include changes in glucocorticoid receptors modification in PBMCs and BAL cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function</measure>
    <time_frame>baseline and week 6</time_frame>
    <description>Secondary outcomes include changes in lung function, which will be assessed with Forced expiratory volume in 1 second percent predicted (FEV1), Forced vital capacity percent predicted (FVC) and Diffusing capacity percent predicted (DLCO).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Beryllium Disease</condition>
  <arm_group>
    <arm_group_label>Mesalamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
    <arm_group_label>Mesalamine</arm_group_label>
    <other_name>Pentasa</other_name>
    <other_name>5-ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic beryllium disease based on the criteria below:

               1. History of beryllium exposure, and;

               2. Positive blood and/or bronchoalveolar lavage Beryllium Lymphocyte Proliferation
                  Tests (BeLPT), and;

               3. Biopsy-proven pathologic changes consistent with CBD-non-caseating granulomas
                  and/or mononuclear cell interstitial infiltrates, and;

               4. Positive bronchoalveolar lavage (BAL) BeLPT and &gt; 15% lymphocytes in BAL fluid.

        Exclusion Criteria:

          -  History of Hepatic disease

          -  History of Renal disease

          -  Hypersensitivity to Pentasa (5-ASA) or salicylates.

          -  Pregnancy

          -  Presence of another disease that may be expected to significantly affect patient
             mortality (e.g., HIV), severe cor pulmonale);

          -  The use of blood thinners.

          -  Current use of tobacco (smoking or otherwise) in the past 6 months

          -  Patient inability to participate in the study, such as inability to undergo
             venipuncture and BAL procedures (if undergoing bronchoscopy) that form part of the
             inclusion/exclusion criteria or part of the outcome measure.

        If undergoing bronchoscopy:

          -  Severe room air hypoxemia (precluding transbronchial lung biopsy and/or BAL), e.g.,
             pO2 &lt; 45 (Denver altitude 5,280 feet);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A. Maier, M.D., MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Day, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <results_first_submitted>September 14, 2017</results_first_submitted>
  <results_first_submitted_qc>November 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Lisa Maier</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Berylliosis</keyword>
  <keyword>Beryllium Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Berylliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesalamine</title>
          <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesalamine</title>
          <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" lower_limit="53" upper_limit="74"/>
                    <measurement group_id="B2" value="62.8" lower_limit="49" upper_limit="79"/>
                    <measurement group_id="B3" value="63.16" lower_limit="49" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6</title>
        <description>Primary endpoints are beryllium proliferation responses (BeLPT) in PBMCs (peripheral blood mononuclear cells) and BAL (bronchoalveolar lavage) cells. The BeLPT is a blood test that measures the immune response to beryllium exposure. If immune cells multiply in response to beryllium, this is considered an abnormal test results. If immune cells do not multiple, this is considered a normal test results. Results are reported as &quot;stimulation index&quot;, which is a ratio of the number of cells grown with beryllium compared to the number of cells grown without beryllium. A value of 2.5 or less is considered normal, and a value greater than 2.5 is abnormal.</description>
        <time_frame>baseline and week 6</time_frame>
        <population>Because bronchoscopy was not required for participation, only three placebo and six 5-ASA-treated subjects underwent bronchoscopy and is reported under BAL.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6</title>
          <description>Primary endpoints are beryllium proliferation responses (BeLPT) in PBMCs (peripheral blood mononuclear cells) and BAL (bronchoalveolar lavage) cells. The BeLPT is a blood test that measures the immune response to beryllium exposure. If immune cells multiply in response to beryllium, this is considered an abnormal test results. If immune cells do not multiple, this is considered a normal test results. Results are reported as &quot;stimulation index&quot;, which is a ratio of the number of cells grown with beryllium compared to the number of cells grown without beryllium. A value of 2.5 or less is considered normal, and a value greater than 2.5 is abnormal.</description>
          <population>Because bronchoscopy was not required for participation, only three placebo and six 5-ASA-treated subjects underwent bronchoscopy and is reported under BAL.</population>
          <units>Stimulation index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BAL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.61" spread="57.18"/>
                    <measurement group_id="O2" value="9.33" spread="14.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBMC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.07" spread="20.30"/>
                    <measurement group_id="O2" value="3.8" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bronchoalveolar Lavage (BAL) Tumor Necrosis Factor Alpha (TNFa)</title>
        <description>Secondary outcomes include changes in bronchoalveolar lavage (BAL) tumor necrosis factor alpha (TNFa)</description>
        <time_frame>baseline and week 6</time_frame>
        <population>We did not have sufficient cells to run experiments on all participants. However, below is a summary of what data was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bronchoalveolar Lavage (BAL) Tumor Necrosis Factor Alpha (TNFa)</title>
          <description>Secondary outcomes include changes in bronchoalveolar lavage (BAL) tumor necrosis factor alpha (TNFa)</description>
          <population>We did not have sufficient cells to run experiments on all participants. However, below is a summary of what data was received.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="35.76"/>
                    <measurement group_id="O2" value="-1750" spread="2734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Steady-state Glutathione (GSH) Levels From Baseline to Week 6</title>
        <description>Secondary outcomes include changes in steady-state GSH levels in beryllium specific CD4+ T cell in bronchoalveolar lavage fluid (BALF)</description>
        <time_frame>baseline and week 6</time_frame>
        <population>We did not receive enough cells from participants to be able to run experiments on all. However, below is a summary of what data was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Steady-state Glutathione (GSH) Levels From Baseline to Week 6</title>
          <description>Secondary outcomes include changes in steady-state GSH levels in beryllium specific CD4+ T cell in bronchoalveolar lavage fluid (BALF)</description>
          <population>We did not receive enough cells from participants to be able to run experiments on all. However, below is a summary of what data was received.</population>
          <units>mmol/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="20.08"/>
                    <measurement group_id="O2" value="10.38" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDAC2 Levels</title>
        <description>Secondary outcomes include changes in HDAC2 levels</description>
        <time_frame>baseline and week 6</time_frame>
        <population>We were not able to perform due to insufficient samples and data collected from each participant to summarize changes in HDAC2 levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>HDAC2 Levels</title>
          <description>Secondary outcomes include changes in HDAC2 levels</description>
          <population>We were not able to perform due to insufficient samples and data collected from each participant to summarize changes in HDAC2 levels.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucocorticoid Receptors</title>
        <description>Secondary outcomes include changes in glucocorticoid receptors modification in PBMCs and BAL cells.</description>
        <time_frame>baseline and week 6</time_frame>
        <population>We were not able to perform due to insufficient samples and data collected from each participant to summarize changes.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucocorticoid Receptors</title>
          <description>Secondary outcomes include changes in glucocorticoid receptors modification in PBMCs and BAL cells.</description>
          <population>We were not able to perform due to insufficient samples and data collected from each participant to summarize changes.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function</title>
        <description>Secondary outcomes include changes in lung function, which will be assessed with Forced expiratory volume in 1 second percent predicted (FEV1), Forced vital capacity percent predicted (FVC) and Diffusing capacity percent predicted (DLCO).</description>
        <time_frame>baseline and week 6</time_frame>
        <population>One participant did not complete follow up in Mesalamine group. However, below is a summary of what data was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function</title>
          <description>Secondary outcomes include changes in lung function, which will be assessed with Forced expiratory volume in 1 second percent predicted (FEV1), Forced vital capacity percent predicted (FVC) and Diffusing capacity percent predicted (DLCO).</description>
          <population>One participant did not complete follow up in Mesalamine group. However, below is a summary of what data was received.</population>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 % pred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="4.49"/>
                    <measurement group_id="O2" value="-0.91" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC % pred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.5"/>
                    <measurement group_id="O2" value="-0.08" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLCO % pred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="4.39"/>
                    <measurement group_id="O2" value="-0.16" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mesalamine</title>
          <description>Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Mesalamine: Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
Placebo: Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mobitz Type II heart block</sub_title>
                <description>In the placebo-treated subjects, we identified a Mobitz Type II heart block during a follow-up bronchoscopy. It was not related to the treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>One 5-ASA-treated subject developed dizziness, constipation, stomach pain and chest pain two weeks</sub_title>
                <description>Dizziness, constipation, stomach pain and chest pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>One 5-ASA-treated subject experienced coughing and low energy after the follow-up bronchoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lisa A. Maier</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>303-398-1983</phone>
      <email>MaierL@NJHealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

